MIDAS VERDICT:

Stock market newcomers have had a rough time this year and many flotations have been pulled before even reaching the finish line. Conviction Life Sciences Company should make the grade, however. The UK life sciences sector has been overlooked and underfunded for years but it is packed full of fascinating companies working their utmost to find cures and treatments for some of the most pernicious diseases in the world. Craig is hoping to raise between £50million and £100million initially, building up to more than £200million. Having worked in the sector for more than seven years and built up a strong following across the investment community, his ambition seems entirely within reach. CLSC should deliver long-term rewards and help a beleaguered industry to find the cash that it sorely needs. There may even be special dividends along the way. At £1, the shares are a buy.